Peptide lexicon
Eloralintid
Long-acting amylin analogue selective for amylin receptors over the calcitonin receptor, in clinical development (LY3841136).
| Substance class | Peptide |
|---|---|
| CAS number | 2883634-40-8 |
| Molecular formula | C₂₀₁H₃₁₉N₄₉O₆₅S₂ |
| Molar mass | 4,526 g/mol |
| Synonyms | LY3841136, Amylin-Rezeptor-Agonist |
| PubChem | CID 175663130 |
Structure
Eloralintide is a synthetic peptide modified for a long duration of action. It acts on amylin receptor complexes (calcitonin receptor plus RAMP) and activates the calcitonin receptor alone much more weakly.
State of research
The compound is being studied in clinical trials; published data cover tolerability, pharmacokinetics and effects on body weight. Preclinically, the focus is on how receptor selectivity shapes efficacy and tolerability.
Status
No marketing authorisation. At Peptidkauf it is available as eloralintide.
Literature
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetesPeptides, 2026 · PMID 41747885 · DOI 10.1016/j.peptides.2026.171480
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical TrialsDiabetes Obes Metab, 2026 · PMID 42452898 · DOI 10.1111/dom.71074
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugsPharmacol Res, 2026 · PMID 42586227 · DOI 10.1016/j.phrs.2026.108382
- Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversiesMetabol Open, 2026 · PMID 41948476 · DOI 10.1016/j.metop.2026.100463
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes MellitusDiabetes Ther, 2026 · PMID 42803913 · DOI 10.1007/s13300-026-01921-0
